A role for SNX1 in the regulation of EGF-dependent phosphorylated EGFR endocytosis via the early/late endocytic pathway in a gefitinib-sensitive human lung cancer cells

Current Signal Transduction Therapy

Volumn 6, Issue 3, 2011, Pages 383-395

  Nishimura, Yukio ^a   Yoshioka, Kiyoko ^b   Takiguchi, Soichi ^c   Bereczky, Biborka ^a   Nakabeppu, Yusaku ^a   Itoh, Kazuyuki ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Endocytosis; Endosomes Lysosomes; Gefitinib; Non small cell lung cancer cell lines; Phosphorylated EGF receptor (pEGFR); Sorting nexin 1 (SNX1)

Indexed keywords

ACTIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; LATRUNCULIN B; SORTING NEXIN; SORTING NEXIN 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; CYTOSKELETON; DRUG SENSITIVITY; ENDOCYTOSIS; ENDOSOME; HUMAN; HUMAN CELL; INTERNALIZATION; LUNG NON SMALL CELL CANCER; LYSOSOME; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TRANSPORT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 80052761109     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436211797484047     Document Type: Article

References (40)

1. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2002; 8: 19-26.
2. Mendelsohn J, Baserga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-65. (Pubitemid 32197693)
3. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 265: 7709-12. (Pubitemid 20158927)
4. Yarden Y. The EGFR family and its ligands in human cancer signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37: 3-8.
5. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-12.
6. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004; 306:1506-7. (Pubitemid 39564935)
7. Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001; 13: 491-8. (Pubitemid 33027902)
8. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11: 1911-4. (Pubitemid 32675316)
9. Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000; 60 Suppl 1: 33-40; discussion 41-2.
10. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-50. (Pubitemid 29255919)
11. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the EGF receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004; 3: 465-72. (Pubitemid 39193724)
12. Nishimura Y, Bereczky B, Ono M. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines. Histochem Cell Biol 2007; 127: 541-53. (Pubitemid 46632449)
13. Nishimura Y, Yoshioka K, Bereczky B, Itoh K. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib- sensitive non-small cell lung cancer cell line. Molecular Cancer 2008; 7: 1-13.
14. Kurten RC, Cadena DL, Gill GN. Enhanced degradation of EGF receptors by a sorting nexin, SNX1. Science 1996; 272: 1008-10. (Pubitemid 26259317)
15. Worby CA, Dixon J E. Sorting out the cellular function of sorting nexins. Nat Rev Mol Cell Biol 2002; 3: 919-31. (Pubitemid 35477370)
16. Horazdovsky BF, Davies BA, Seaman MN, McLaughlin SA, Yoon S, Emr SD. A sorting nexin-1 homologue, Vps5p, forms a complex with Vps17p and is required for recycling the vacuolar proteinsorting receptor. Mol Biol Cell 1997; 8: 1529-41. (Pubitemid 27385574)
17. Nothwehr SF, Hindes AE. The yeast VPS5/GRD2 gene encodes a sorting nexin-1-like protein required for localizing membrane proteins to the late Golgi. J Cell Sci 1997; 110: 1063-72. (Pubitemid 27232276)
18. Seaman MN, McCaffery JM, Emr SD. A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. J Cell Biol 1998; 142: 665-81. (Pubitemid 28381486)
19. Zhong Q, Lasar CS, Tronchere H, et al. Endosomal localization and function of sorting nexin 1. Proc Natl Acad Sci USA 2002; 99: 6767-72. (Pubitemid 34526206)
20. Carlton J, Bujny M, Peter BJ, et al. Sorting nexin-1 mediates tubular endosome-to-TGN transport through coincidence sensing of high-curvature membranes and 3-phosphoinositides. Curr Biol 2004; 14: 1791-00.
21. Gullapalli A, Garrett TA, Paing MM, Griffin CT, Yang Y, Trejo J. A role for sorting nexin 2 in epidermal growth factor receptor down-regulation: evidence for distinct functions of sorting nexin 1 and 2 in protein trafficking. Mol Biol Cell 2004; 15: 2143-55. (Pubitemid 38580634)
22. Nishimura Y, Higaki M, Kato K. Identification of a precursor form of cathepsin D in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Biochem Biophys Res Commun 1987; 148: 335-43.
23. Nishimura Y, Kawabata T, Kato K. Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch Biochem Biophys 1988; 261: 64-71. (Pubitemid 18070781)
24. Okazaki I, Himeno M, Ezaki J, Ishikawa T, Kato K. Purification and characterization of an 85 kDa sialoglycoprotein in rat liver. J Biochem 1992; 111: 763-9.
25. Nishimura Y, Itoh K, Yoshioka K, Tokuda K, Himeno M. Overexpression of ROCK in human breast cancer cells. Evidence that ROCK activity mediates intracellular membrane traffic of lysosomes. Pathol Oncol Res 2003; 9: 83-95. (Pubitemid 36958628)
26. Nishimura Y, Yoshioka K, Bernard O, Himeno M, Itoh K. LIM kinase 1: evidence for a role in the regulation of intracellular vesicle trafficking of lysosomes and endosomes in human breast cancer cells. Eur J Cell Biol 2004; 34: 369-80. (Pubitemid 39307174)
27. Nishimura Y, Yoshioka K, Bernard O, Bereczky B, Itoh K. A role of LIM kinase 1/cofilin pathway in regulating endocytic trafficking of EGF receptor in human breast cancer cells. Histochem Cell Biol 2006; 126: 627-38. (Pubitemid 44484907)
28. Kornfeld S, Mellman I. The biogenesis of lysosomes. Ann Rev Cell Biol 1989; 5:483-525. (Pubitemid 19286692)
29. Sandoval IV, Arredondo JJ, Alcalde J, et al. The residues Leu (Ile) 475-Ile (Leu) 476, contained in the extended carboxyl cytoplasmic tail, are critical for targeting of the resident lysosomal membrane protein LIMPII to lysosomes. J Biol Chem 1994; 269: 6622-31.
30. Sandoval I, Martinez-Arca S, Valdueza J, et al. Distinct reading of different structural determinants modulates the dileucine-mediated transport steps of the lysosomal membrane protein LIMPII and the insulin-sensitive glucose transporter GLUT4. J Biol Chem 2000; 275: 39874-85. (Pubitemid 32064607)
31. Gaidarov I, Santini F, Warren RA, Keen JH. Spatial control of coated-pit dynamics in living cells. Naure Cell Biol 1999; 1: 1-8.
32. Haft CR, de la Luz Sierra M, Barr VA, Haft DH, Taylor SI. Identification of a family of sorting nexin molecules and characterization of their association with receptors. Mol Cell Biol 1998; 18: 7278-87. (Pubitemid 28533047)
33. Stoorvogel W, Kerstens S, Fritzsche I, et al. Sorting of ligandactivated epidermal growth factor receptor to lysosomes requires its actin-binding domain. J Biol Chem 2004; 279: 11562-9. (Pubitemid 38401657)
34. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97:643-55. (Pubitemid 40812628)
35. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancermolecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44. (Pubitemid 41058345)
36. Reinmuth N, Meister M, Muley T, et al. Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. Int J Cancer 2006; 119: 727-34. (Pubitemid 44051433)
37. Johnson BE, Jänne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005; 65: 7525-9. (Pubitemid 41297219)
38. Jänne PA. Gefitinib for epidermal growth factor receptor mutant lung cancers: Searching for a weapon of mass destruction. J Clin Oncol 2006; 24: 3319-21. (Pubitemid 46638881)
39. Jänne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2006; 12: 4416-20.
40. Sodella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-7. (Pubitemid 39100331)